Neoplasia and CancerExplore Recent Advances and Discoveries

Stay up to date on molecular insights and new treatments with articles, sessions, and the latest guidelines.

Estetrol (E4) Shows Promise as a Safe Effective Drug for Use in Advanced Prostate Cancer
April 3, 2017 | The natural fetal estrogen estetrol, also called E4, is being tested as a new drug that may help treat advanced prostate cancer, according to an ongoing industry-sponsored study&hellip

Recent Thyroid Cancer Trends in the United States Suggest Age, Racial Disparities
April 1, 2017 | In the United States, thyroid cancer incidence is rising among young people as well as Hispanics and African Americans, a new study reports. Results of this research…

Exposure to BPA Substitute, BPS, Multiplies Breast Cancer Cells
April 1, 2017 | Bisphenol S (BPS), a substitute for the chemical bisphenol A (BPA) in the plastic industry, shows the potential for increasing the aggressiveness of breast cancer through its behavior as an endocrine-disrupting chemical…

Exposure to Common Flame Retardants May Raise the Risk of Papillary Thyroid Cancer
April 1, 2017 | Some flame retardants used in many home products appear to be associated with the most common type of thyroid cancer, papillary thyroid cancer (PTC), according to a new study…

Unique Biomarkers Identified for Use in Thyroid Cancer Follow-Up
January 2017 | Researchers have identified two unique biomarkers that show promise for monitoring patients who have received treatment for papillary thyroid cancer (PTC), according to a study recently published in the new open access Journal of the Endocrine Society…

Commentary: The Risk of Hypothyroidism in Some Thyroid Cancer Patients
January 2017 | The American Cancer Society estimates that among the 62,450 people who will be diagnosed with thyroid cancer in 2016, some will be treated with thyroidectomy…

Blood Biomarkers Identified in Drug-Resistant Cancer Tumor Cells
November 2016 | While searching for a non-invasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with…

Cautiously Optimistic: The Future of Pancreatic Cancer Treatments
October 2016 | As survival rates from pancreatic cancer slowly inch upward, a new drug therapy may offer patients a brighter outlook. For many decades, a diagnosis of pancreatic cancer…

Fairytales: Dispelling Pediatric Thyroid Cancer Myths
June 2015 | Misrepresentations surround the occurrence, causes, and treatment of thyroid cancer in the pediatric patient population. It’s not as “rare” as once thought, and despite its treatability…

Explore highlights of current education across the Endocrine Society.


Selecting a Target in Refractory Cushing Disease
ENDO Session | No credit available
Maria Fleseriu, MD
What’s your best option? Use the latest information on medical therapies from clinical trials to treat your patients with persistent disease.

Clinical Management of Adrenocortical Carcinoma
ENDO Session | No credit available
Martin Fassnacht, MD
Review the options, as well as the pros and cons for each step in surgical and medical management of ACC.

Evaluation and Management of Neuroendocrine Tumors
ENDO Session | No credit available
Faculty: Karel Pacak, MD; Wouter W. de Herder, MD; and Thomas M. O’Dorisio
Hear cases, learn strategies, and test yourself on the diagnosis, localization, and treatment of NETs.

Hormones and Cancer Digital Toolkit
Patient Resource | No credit available
Reviewer: Richard J. Santen, MD
Interactive and downloadable resources and information for patients with questions about endocrine-related cancers.

Explore highlights of current publications across the Endocrine Society journals. Visit academic.oup.com/endocrinesociety for more.


Cancer Risks in Patients Treated with Growth Hormone in Childhood: The SAGhE European Cohort Study
JCEM | February 10, 2017
Anthony J Swerdlow, Rosie Cooke, Dominique Beckers, Birgit Borgström, Gary Butler, Jean-Claude Carel, Stefano Cianfarani, Peter Clayton, Joël Coste, Annalisa Deodati, Emmanuel Ecosse, Ruth Gausche, Claudio Giacomozzi, Anita CS. Hokken-Koelega, Aysha J Khan, Wieland Kiess, Claudia E. Kuehni, Primus-E. Mullis, Roland Pfaffle, Lars Sävendahl, Grit Sommer, Muriel Thomas, Anders Tidblad, Sally Tollerfield, Liesbet Van Eycken, and Gladys RJ. Zandwijken
Context: Growth Hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited…

Whole-Exome Sequencing Study of Thyrotropin-Secreting Pituitary Adenomas
JCEM | November 17, 2016
Santosh Sapkota, Kazuhiko Horiguchi, Masahiko Tosaka, Syozo Yamada, and Masanobu Yamada
Thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) account for 0.5% to 2.8% of all pituitary adenomas…

Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
JCEM | October 18, 2016
Weibin Wang, Helen Kang, Yinu Zhao, Irene Min, Brian Wyrwas, Maureen Moore, Lisong Teng, Rasa Zarnegar, Xuejun Jiang, and Thomas J. Fahey, III
Thyroid cancer incidence has increased significantly in recent years, and it is currently the fifth most frequently diagnosed…

Long-Term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study
JCEM | October 12, 2016
Yul Hwangbo, Jung Min Kim, Young Joo Park, Eun Kyung Lee, You Jin Lee, Do Joon Park, Young Sik Choi, Kang Dae Lee, Seo Young Sohn, Sun Wook Kim, Jae Hoon Chung, Dong Jun Lim, Min Hee Kim, Min Joo Kim, Young Suk Jo, Min Ho Shong, Sung-Soo Koong, Jong Ryeal Hahm, Jung Hwa Jung, and Ka Hee Yi
Thyroid cancer is the most common malignancy in Korea. According to the statistics of the Korea Central Cancer Registry…

Clinical, Sonographic, and Pathological Characteristics of RAS-Positive versus BRAF-Positive Thyroid Carcinoma
JCEM | September 30, 2016
Sujay Kakarmath, Howard T. Heller, Caroline A. Alexander, Edmund S. Cibas, Jeffrey F. Krane, Justine A. Barletta, Neal I. Lindeman, Mary C. Frates, Carol B. Benson, Atul A. Gawande, Nancy L. Cho, Matthew Nehs, Francis D. Moore, Ellen Marqusee, Mathew I. Kim, P. Reed Larsen, Norra Kwong, Trevor E. Angell, and Erik K. Alexander
Mutations in the BRAF and RAS oncogenes are responsible for most well-differentiated thyroid cancer. Yet, our clinical understanding of how BRAF-positive and RAS-positive thyroid cancers…

P450 Oxidoreductase Deficiency: Loss of Activity Caused by Protein Instability From a Novel L374H Mutation
JCEM | September 7, 2016
Shaheena Parween, Florence Roucher-Boulez, Christa E. Flück, Anne Lienhardt-Roussie, Delphine Mallet, Yves Morel, and Amit V. Pandey
Context: P450 oxidoreductase (POR) is required for the activities of steroid-metabolizing cytochrome P450 enzymes in the endoplasmic reticulum. POR deficiency (PORD) is a form of…

Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin
JCEM | September 7, 2016
Rachel J. Watkins, Waraporn Imruetaicharoenchoke, Martin L. Read, Neil Sharma, Vikki L. Poole, Erica Gentilin, Sukhchain Bansal, Emy Bosseboeuf, Rachel Fletcher, Hannah R. Nieto, Ujjal Mallick, Allan Hackshaw, Hisham Mehanna, Kristien Boelaert, Vicki E. Smith, and Christopher J. McCabe
Context: Metastatic disease is responsible for the majority of endocrine cancer deaths. New therapeutic targets are urgently needed to improve patient survival rates. Objective…

Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience
JCEM | August 29, 2016
Liborio Torregrossa, David Viola, Elisa Sensi, Mirella Giordano, Paolo Piaggi, Cristina Romei, Gabriele Materazzi, Paolo Miccoli, Rossella Elisei, and Fulvio Basolo
The large majority of thyroid cancer is represented by papillary thyroid carcinoma (PTC), which accounts for more than 80% of all thyroid malignancies. BRAF is a member of the RAF kinase…

A Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1
JCEM | June 2, 2016
Øyvind Bruserud, Bergithe E. Oftedal, Nils Landegren, Martina M. Erichsen, Eirik Bratland, Kari Lima, Anders P. Jørgensen, Anne G. Myhre, Johan Svartberg, Kristian J. Fougner, Åsne Bakke, Bjørn G. Nedrebø, Bjarne Mella, Lars Breivik, Marte K. Viken, Per M. Knappskog, Mihaela C. Marthinussen, Kristian Løvås, Olle Kämpe, Anette B. Wolff, and Eystein S. Husebye
Context: Autoimmune polyendocrine syndrome type 1 (APS1) is a childhood-onset monogenic disease defined by the presence of two of the three major components: hypoparathyroidism, primary…

Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients with Missense AIP Mutations
JCEM | June 2, 2016
Laura C. Hernández-Ramírez, Federico Martucci, Rhodri M. L. Morgan, Giampaolo Trivellin, Daniel Tilley, Nancy Ramos-Guajardo, Donato Iacovazzo, Fulvio D'Acquisto, Chrisostomos Prodromou and Márta Korbonits
Context: The pathogenic effect of mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene (AIPmuts) in pituitary adenomas is incompletely understood. We have identified…

For a complete list of Endocrine Society guidelines, visit endocrine.org/guidelines.


Treatment of Cushing's Syndrome
JCEM | July 29, 2015
Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, M. Hassan Murad, John Newell-Price, Martin O. Savage, and Antoine Tabarin
Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes…

Diagnosis and Treatment of Pheochromocytoma and Paraganglioma
JCEM | June 03, 2014
Jacques W. M. Lenders, Quan-Yang Duh, Graeme Eisenhofer, Anne-Paule Gimenez-Roqueplo, Stefan K. G. Grebe, Mohammad Hassan Murad, Mitsuhide Naruse, Karel Pacak, and William F. Young Jr
The Task Force recommends that initial biochemical testing for PPGLs should include measurements of plasma free or urinary fractionated metanephrines. Consideration should be given to preanalytical factors…

The Diagnosis of Cushing's Syndrome
JCEM | January 14, 2009
Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, John Newell-Price, Martin O. Savage, Paul M. Stewart, and Victor M. Montori
After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with…

For additional meetings, visit the Endocrine Society’s Worldwide Endocrinology Calendar at endocrine.org/calendar.


Clinical Endocrinology Update & Endocrine Board Review
Dates: September 23–27, 2017
Location: Chicago, Illinois, United States
Sponsor: Endocrine Society
Whether you need the latest clinical information or you’re preparing to certify or recertify for the boards, Clinical Endocrinology Update (CEU) and Endocrine Board Review (EBR) have you covered.

ENDO Bridge
Dates: October 19–22, 2017
Location: Antalya, Turkey
Sponsor: Endocrine Society, the European Society of Endocrinology, and The Society of Endocrinology and Metabolism of Turkey
EndoBridge will provide a comprehensive update in the field of endocrinology for the clinical endocrinologist. The official language of the meeting is English, but simultaneous translation will be available in Russian, Arabic, and Turkish

ENDO 2018
Dates: March 17–20, 2018
Location: Chicago, Illinois, United States
Sponsor: Endocrine Society
ENDO is the world’s largest event for presenting and obtaining the latest in endocrine science and medicine with an extensive program covering a broad array of topics, various networking opportunities, poster sessions, updates on new products and technologies at the ENDOExpo, and more.

Resources